Payers, politicians and some regulators have been balking at the $84,000 price tag on Gilead’s ($GILD) hepatitis C treatment Sovaldi ever since it hit the market in January. Now two
Rite Aid reported this week that its earnings per share totaled $0.04 last quarter, but the news did little to boost share prices, which have been sliding since the company
Problems surrounding an Indian company’s launch of generic versions of three blockbuster drugs have preserved millions in revenue for the brand-name makers, reports The Wall Street Journal. Meanwhile, Swiss pharmaceutical
In a few years, the first blockbusters of the biotech age will begin to face generic competition. Big drugs like Amgen’s AMGN +2.54% Epogen and Neulasta, Roche and Biogen Idec’s
Medicare, the federal health insurance program for Americans 65 and older, could save $18 billion over the next 10 years if doctors switch to a less expensive drug to treat
Generic drug companies are beyond the jurisdiction of the Patented Medicine Prices Review Board, the Federal Court has ruled in twin cases involving generic drug makers Ratiopharm (now Teva Canada)
There are few greater economic challenges facing American families and taxpayers than the high cost of healthcare. High health costs result in lower incomes, higher premiums and out-of-pocket costs, fewer
While many patients believe that generic drugs are exact copies of their brand name brothers, the body often absorbs generic medication at a different rate, and federal regulators do not
Never mind the FDA crackdown on Indian drug makers for quality control problems. Sales of prescription drugs to the U.S. by the Indian pharmaceutical industry likely wont take a huge
Pharmacist Larry Cowan can flip through his records and spot the generic drugs that have taken big price jumps in the past year or so. Theres digoxin, a heart medicine
